Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention and reoccurrence of the disease, risk assessment and prevention of stroke, ventricular rate control, and rhythm control. The choice of treatment is based on the cause and the time elapsed since the onset of symptoms. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin) and anticoagulation therapy (e.g., vitamin K antagonists, novel oral anticoagulants [NOACs]). Surgical treatment is also an option for some patients. This claims data analysis shows treatment patterns and brand share by line of therapy for newly diagnosed and recently treated AF patients in United States.
Questions answered
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Cardinal Health, Janssen Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo, Almatica Pharma, Woodward Pharma, Baxter Healthcare, Validus Pharmaceuticals.
Key drugs: Vitamin K antagonists; NOACs; class Ia, Ic, and III antiarrhythmics; beta blockers; calcium channel blockers; digitalis glycosides; antiplatelet agents.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.